Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER-2/neu and bcl-2 in Ovarian Carcinoma Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival

HER-2/neu and bcl-2 in Ovarian Carcinoma Clinicopathologic, Immunohistochemical, and... RESEARCH ARTICLE HER-2/neu and bcl-2 in Ovarian Carcinoma Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival Maria Rosaria Raspollini, MD,* Gianni Amunni, MD,w Alessandro Villanucci, MD,w Francesca Castiglione, MD,* Duccio Rossi Degl’Innocenti, BSc,* Gianna Baroni, BSc,* Milena Paglierani, BSc,* and Gian Luigi Taddei, MD* varian cancer is the most common cause of cancer- Abstract: The bcl-2 protein is a membrane protein involved in Orelated death among the gynecologic tumors. Serous prolonging cell survival by inhibiting apoptosis. The HER-2 carcinoma, the most common malignant ovarian tumor, oncogene, which is located on chromosome 17 and encodes for a is generally diagnosed at later stages, and its survival rate tyrosine-kinase growth factor receptor, is amplified and HER-2/ is low. Approximately 90% of all women with ovarian neu is overexpressed in 25% to 30% of breast carcinomas. The carcinoma are treated by surgery followed by chemothe- authors analyzed the bcl-2 expression and the bcl-2 gene and rapy. Chemotherapy is required to eradicate the micro- HER-2/neu overexpression and amplification in FIGO stage scopic disease that is frequently present due to the pattern IIIC, serous, G3, ovarian carcinomas obtained from living of peritoneal carcinomatosis in the majority of patients patients who http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

HER-2/neu and bcl-2 in Ovarian Carcinoma Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/her-2-sol-neu-and-bcl-2-in-ovarian-carcinoma-clinicopathologic-1YLPHypDR1

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1062-3345
eISSN
1533-4058
DOI
10.1097/01.pai.0000155192.94214.f9
pmid
16785787
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE HER-2/neu and bcl-2 in Ovarian Carcinoma Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival Maria Rosaria Raspollini, MD,* Gianni Amunni, MD,w Alessandro Villanucci, MD,w Francesca Castiglione, MD,* Duccio Rossi Degl’Innocenti, BSc,* Gianna Baroni, BSc,* Milena Paglierani, BSc,* and Gian Luigi Taddei, MD* varian cancer is the most common cause of cancer- Abstract: The bcl-2 protein is a membrane protein involved in Orelated death among the gynecologic tumors. Serous prolonging cell survival by inhibiting apoptosis. The HER-2 carcinoma, the most common malignant ovarian tumor, oncogene, which is located on chromosome 17 and encodes for a is generally diagnosed at later stages, and its survival rate tyrosine-kinase growth factor receptor, is amplified and HER-2/ is low. Approximately 90% of all women with ovarian neu is overexpressed in 25% to 30% of breast carcinomas. The carcinoma are treated by surgery followed by chemothe- authors analyzed the bcl-2 expression and the bcl-2 gene and rapy. Chemotherapy is required to eradicate the micro- HER-2/neu overexpression and amplification in FIGO stage scopic disease that is frequently present due to the pattern IIIC, serous, G3, ovarian carcinomas obtained from living of peritoneal carcinomatosis in the majority of patients patients who

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Jun 1, 2006

There are no references for this article.